IUPAC/Chemical Name
2-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methoxy)-2-methylpropanoic acid
InChi Key
LNXXSBRGLBOASF-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H16ClNO4/c1-9-12(8-20-15(2,3)14(18)19)21-13(17-9)10-4-6-11(16)7-5-10/h4-7H,8H2,1-3H3,(H,18,19)
SMILES Code
CC(C)(OCC1=C(C)N=C(C2=CC=C(Cl)C=C2)O1)C(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
309.74
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Bloxham DP, Bradshaw D, Cashin CH, Dodge BB, Lewis EJ, Westmacott D, Self CR. Biologic properties of romazarit (Ro 31-3948), a potential disease-modifying antirheumatic drug. J Pharmacol Exp Ther. 1990 Mar;252(3):1331-40. PubMed PMID: 2156999.
2: Holford NH, Williams PE, Muirhead GJ, Mitchell A, York A. Population pharmacodynamics of romazarit. Br J Clin Pharmacol. 1995 Mar;39(3):313-20. PubMed PMID: 7619674; PubMed Central PMCID: PMC1365009.
3: Williams PE, Muirhead GJ, Worth E, Zimmer R, Lücker P. Pharmacokinetics and tolerance of romazarit after oral administration of ascending single doses to healthy human volunteers. Eur J Drug Metab Pharmacokinet. 1990 Oct-Dec;15(4):317-22. PubMed PMID: 2088768.
4: Williams PE, Bird HA, Minty S, Helliwell PS, Muirhead GJ, Bentley J, York A. A pharmacokinetic and tolerance study of romazarit in patients with rheumatoid arthritis. Biopharm Drug Dispos. 1992 Mar;13(2):119-29. PubMed PMID: 1550907.
5: Self CR, Barber WE, Machin PJ, Osbond JM, Smithen CE, Tong BP, Wickens JC, Bloxham DP, Bradshaw D, Cashin CH, et al. Romazarit: a potential disease-modifying antirheumatic drug. J Med Chem. 1991 Feb;34(2):772-7. PubMed PMID: 1995900.
6: Sharma RN, Xavier FP, Vasu KK, Chaturvedi SC, Pancholi SS. Synthesis of 4-benzyl-1,3-thiazole derivatives as potential anti-inflammatory agents: an analogue-based drug design approach. J Enzyme Inhib Med Chem. 2009 Jun;24(3):890-7. doi: 10.1080/14756360802519558. PubMed PMID: 19469712.
7: Pillai AD, Rathod PD, Xavier FP, Padh H, Sudarsanam V, K Vasu K. Tetra substituted thiophenes as anti-inflammatory agents: exploitation of analogue-based drug design. Bioorg Med Chem. 2005 Dec 15;13(24):6685-92. Epub 2005 Aug 24. PubMed PMID: 16125391.
8: Seed MP, Gardner CR. The modulation of intra-articular inflammation, cartilage matrix and bone loss in mono-articular arthritis induced by heat-killed Mycobacterium tuberculosis. Inflammopharmacology. 2005;12(5-6):551-67. PubMed PMID: 16259721.
